… were introduced into the clinic for cancer patients in 2003. … Cancer Research UK and Pfizer
GRD. A PARP inhibitory dose (PID) of AG014699 of 12 mg/m 2 /d was established by treating …

… Cancer cells frequently harbor defects in DNA repair pathways, leading to genomic … poly(ADP)
ribose polymerase. This provides the basis for a novel synthetic lethal approach to cancer …

… As the name implies, PARP enzymes modify DNA-associated proteins by adding chains of
ADP ribose units. To date, 17 members of the PARP family have been identified on the basis …

… the use of these agents in cancer therapy, providing data from … initial clinical trials of PARP
inhibitors for cancer treatment. … to treat cancers with PARP inhibitors included in clinical trials. …

… proof-of-concept for targeting cancers in BRCA mutation carriers with PARP inhibitors.84, …
; 54 breast cancer patients and 56 ovarian cancer patients with advanced heavily pre-treated …

… the treatment of several types of cancer, and PARP inhibitors have also shown therapeutic
potential in treating … resistance during cancer therapy and repurposing PARP inhibitors for the …

… ADP-ribose) polymerase (PARP) inhibitors represent one of the successful novel approaches
to targeted cancer treatment… for the treatment of breast and ovarian cancers. Despite the …

… The treatment of triple-negative breast cancer with poly(ADP-ribose) polymerase (PARP) …
Inhibition of poly(ADP-ribose) polymerase (PARP) is emerging as one of the most exciting …

… Understanding the mechanisms of action of PARP inhibitors may assist physicians in selecting
the most appropriate drug for treating cancer. The effectiveness in PARP trapping may be …

… often presents genome instability, with almost half of the ovarian cancers harbor defects in …
-deficient cancers in recent years. The multi-functional enzyme Poly ADP ribose polymerase (…